ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (ConTTRibute)

Overview

About this study

The objectives of this study are to describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients, to characterize the safety and effectiveness of patisiran as part of routine clinical practice in the real-world clinical setting, and to describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) mutation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
* Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis

Exclusion Criteria:

* Current enrollment in a clinical trial for any investigational agent

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/16/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Elizabeth Mauricio, M.D.

Open for enrollment

Contact information:

Amber Baskin M.H.A.

Baskin.Amber@mayo.edu

More information

Publications

Publications are currently not available